HUE046780T2 - Kannabidiol használata aripiprazollal kombinálva - Google Patents
Kannabidiol használata aripiprazollal kombinálvaInfo
- Publication number
- HUE046780T2 HUE046780T2 HUE16167562A HUE16167562A HUE046780T2 HU E046780 T2 HUE046780 T2 HU E046780T2 HU E16167562 A HUE16167562 A HU E16167562A HU E16167562 A HUE16167562 A HU E16167562A HU E046780 T2 HUE046780 T2 HU E046780T2
- Authority
- HU
- Hungary
- Prior art keywords
- cannabidiol
- aripiprazole
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0800390A GB2456183A (en) | 2008-01-04 | 2008-01-04 | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE046780T2 true HUE046780T2 (hu) | 2020-03-30 |
Family
ID=39144704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13152600A HUE047214T2 (hu) | 2008-01-04 | 2008-12-17 | Kannabinoidok használata aripiprazollal kombinálva |
| HUE16167562A HUE046780T2 (hu) | 2008-01-04 | 2008-12-17 | Kannabidiol használata aripiprazollal kombinálva |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13152600A HUE047214T2 (hu) | 2008-01-04 | 2008-12-17 | Kannabinoidok használata aripiprazollal kombinálva |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9017737B2 (enExample) |
| EP (3) | EP2249848B1 (enExample) |
| JP (1) | JP5409650B2 (enExample) |
| KR (1) | KR101631518B1 (enExample) |
| CN (1) | CN101939017B (enExample) |
| AR (1) | AR070063A1 (enExample) |
| AU (1) | AU2008346285B2 (enExample) |
| BR (1) | BRPI0821461A8 (enExample) |
| CA (1) | CA2708921C (enExample) |
| CL (1) | CL2008003902A1 (enExample) |
| CO (1) | CO6290695A2 (enExample) |
| ES (3) | ES2750728T3 (enExample) |
| GB (3) | GB2456183A (enExample) |
| HU (2) | HUE047214T2 (enExample) |
| IL (1) | IL206784A0 (enExample) |
| MX (1) | MX2010007073A (enExample) |
| NZ (1) | NZ586648A (enExample) |
| PE (2) | PE20141249A1 (enExample) |
| PL (2) | PL2609928T3 (enExample) |
| PT (2) | PT3095452T (enExample) |
| RU (1) | RU2503448C2 (enExample) |
| TW (2) | TWI519299B (enExample) |
| UA (1) | UA103472C2 (enExample) |
| WO (1) | WO2009087351A1 (enExample) |
| ZA (1) | ZA201005443B (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| GB2377218A (en) * | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| EP1811983B1 (en) | 2004-11-16 | 2020-10-07 | GW Pharma Limited | New use for cannabinoid |
| GB2459637B (en) * | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| EP2551255B1 (en) * | 2010-03-26 | 2017-11-08 | Vivacell Biotechnology España, S.L | Cannabinoid quinone derivatives |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| US8445034B1 (en) | 2010-11-02 | 2013-05-21 | Albert L Coles, Jr. | Systems and methods for producing organic cannabis tincture |
| US9775379B2 (en) | 2010-12-22 | 2017-10-03 | Syqe Medical Ltd. | Method and system for drug delivery |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| JP6562912B2 (ja) * | 2013-06-26 | 2019-08-21 | アムジェン インコーポレイテッド | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| CA2929321C (en) | 2013-10-29 | 2022-04-05 | Echo Pharmaceuticals B.V. | Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders |
| US9616025B2 (en) | 2013-10-29 | 2017-04-11 | Echo Pharmaceuticals B.V. | Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| IL273507B2 (en) | 2014-06-30 | 2024-06-01 | Syqe Medical Ltd | Methods, devices and systems for administering active substances through the lungs |
| ES2898173T3 (es) | 2014-06-30 | 2022-03-04 | Syqe Medical Ltd | Dispositivos y sistemas para la administración pulmonar de principios activos |
| US11298477B2 (en) | 2014-06-30 | 2022-04-12 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
| US10099020B2 (en) | 2014-06-30 | 2018-10-16 | Syqe Medical Ltd. | Drug dose cartridge for an inhaler device |
| EP3160558B1 (en) | 2014-06-30 | 2020-02-12 | Syqe Medical Ltd. | Flow regulating inhaler device |
| CN106573118B (zh) * | 2014-06-30 | 2020-07-03 | Syqe医药有限公司 | 用于活性剂的肺部递送的方法、装置及系统 |
| EP3954417A1 (en) | 2014-06-30 | 2022-02-16 | Syqe Medical Ltd. | Method and device for vaporization and inhalation of isolated substances |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| US9539295B2 (en) | 2014-12-05 | 2017-01-10 | Bradley Michael Bohus | Cannabidiol (CBD) enriched alcohol |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2542155B (en) * | 2015-09-09 | 2018-08-01 | Gw Pharma Ltd | Use of cannabidiol in the treatment of mental disorders |
| RU2020128323A (ru) | 2015-12-22 | 2020-10-06 | Зодженикс Интернэшнл Лимитед | Фенфлураминовые композиции и способы их получения |
| EP3393470B1 (en) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| ES2874087T3 (es) | 2016-01-06 | 2021-11-04 | Syqe Medical Ltd | Tratamiento terapéutico con dosis bajas |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| JP2019524655A (ja) | 2016-06-29 | 2019-09-05 | キャンサイエンス イノベーションズ インコーポレーテッドＣａｎｎｓｃｉｅｎｃｅ Ｉｎｎｏｖａｔｉｏｎｓ Ｉｎｃ． | 脱炭酸大麻樹脂、その使用、及びそれを製造する方法 |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| US11701348B1 (en) | 2016-07-23 | 2023-07-18 | Turtle Bear Holdings, Llc | Psilocybin compositions |
| US20210069170A1 (en) | 2016-07-23 | 2021-03-11 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
| KR20250040753A (ko) * | 2016-08-24 | 2025-03-24 | 조게닉스 인터내셔널 리미티드 | 5-ht2b 작용물질의 형성을 억제하기 위한 제제 및 그것의 사용 방법 |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| US10835501B2 (en) | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
| CN108078984B (zh) * | 2016-11-23 | 2020-11-20 | 汉义生物科技（北京）有限公司 | 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用 |
| CN108143726B (zh) * | 2016-12-02 | 2020-05-08 | 汉义生物科技（北京）有限公司 | 大麻二酚与5-ht2a受体拮抗剂及5-ht再摄取抑制剂的药物组合物及其用途 |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| AU2017384392B2 (en) | 2016-12-20 | 2023-05-25 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| AU2017384526B2 (en) | 2016-12-20 | 2023-11-02 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US20190142851A1 (en) * | 2017-11-16 | 2019-05-16 | CaaMTech, LLC | Compositions comprising a psilocybin derivative and a cannabinoid |
| US11974984B2 (en) | 2017-02-09 | 2024-05-07 | Caamtech, Inc. | Compositions and methods comprising a combination of serotonergic drugs |
| US12414936B2 (en) | 2017-02-09 | 2025-09-16 | Caamtech, Inc. | Compositions comprising a serotonergic tryptamine compound |
| EP3579832A4 (en) * | 2017-02-09 | 2020-12-30 | Caamtech, LLC | COMPOSITIONS AND PROCESSES INCLUDING A PSILOCYBIN DERIVATIVE |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
| CN107469087A (zh) * | 2017-09-10 | 2017-12-15 | 孙永丽 | 用于治疗精神病的制剂 |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| JP2021505595A (ja) | 2017-12-05 | 2021-02-18 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 結晶形およびその製造方法 |
| CN118593482A (zh) | 2017-12-05 | 2024-09-06 | 赛诺维信制药公司 | 非外消旋混合物及其用途 |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| PL3755318T3 (pl) * | 2018-02-20 | 2022-12-19 | Mymd Pharmaceuticals, Inc. | Genetycznie zmodyfikowane rośliny cannabis sativa i zmodyfikowane związki kannabinoidowe do leczenia uzależnień od substancji i innych zaburzeń |
| EP3790537A1 (en) | 2018-05-11 | 2021-03-17 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| EP3883555A1 (en) | 2018-11-19 | 2021-09-29 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| WO2020188569A1 (en) * | 2019-03-20 | 2020-09-24 | Bol Pharma Ltd. | Methods and compositions for preventing or treating weight gain caused by psychiatric drugs |
| SG11202113266YA (en) | 2019-06-04 | 2021-12-30 | Sunovion Pharmaceuticals Inc | Modified release formulations and uses thereof |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| US11660305B2 (en) | 2019-11-19 | 2023-05-30 | Turtle Bear Holdings, Llc | Tryptamine compositions for enhancing neurite outgrowth |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| EP4188090A4 (en) | 2020-07-28 | 2024-08-14 | Impello Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MODIFYING SECONDARY METABOLITES IN PLANTS |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| US20240000808A1 (en) * | 2020-11-16 | 2024-01-04 | Orcosa Inc. | Improved use of cannabinoids in the treatment of alzheimer's disease |
| US11337934B1 (en) | 2021-04-08 | 2022-05-24 | Lanny Leo Johnson | Compositions including a cannabinoid and protocatechuic acid |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| IL136839A (en) * | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
| US7053092B2 (en) * | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| CA2422708C (en) * | 2001-03-22 | 2010-10-26 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| US20050154202A1 (en) * | 2002-04-05 | 2005-07-14 | Hagmann William K. | Substituted aryl amides |
| DE10226494A1 (de) * | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
| GB2392093B (en) * | 2002-08-14 | 2006-03-08 | Gw Pharma Ltd | Pharmaceutical formulations |
| GB0222077D0 (en) | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
| AU2003295235B2 (en) | 2002-12-27 | 2008-06-19 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| CN1794994A (zh) * | 2003-05-23 | 2006-06-28 | 大塚制药株式会社 | 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂 |
| WO2005000830A1 (en) * | 2003-06-24 | 2005-01-06 | Gw Pharma Limited | Pharmaceutical compositions comprising cabbinochreme type compounds |
| CA2537535A1 (en) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Novel medical use of selective cb1-receptor antagonists |
| US20070105914A1 (en) * | 2003-09-18 | 2007-05-10 | Armstrong Helen M | Substituted sulfonamides |
| SA04250288B1 (ar) * | 2003-09-19 | 2008-07-19 | سولفاي فارماسوتيكالز بي . في | مشتقات ثيازول thiazole كمعدلات لمستقبل المكونات الكيميائية للقنب cannabinoid |
| BRPI0417771A (pt) * | 2003-12-19 | 2007-04-17 | Bristol Myers Squibb Co | heterociclos azabicìclicos como moduladores de receptor canabinóides |
| WO2006017892A1 (en) * | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
| GB0425248D0 (en) * | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| EP1811983B1 (en) * | 2004-11-16 | 2020-10-07 | GW Pharma Limited | New use for cannabinoid |
| FR2882931B1 (fr) * | 2005-03-14 | 2007-05-18 | Sanofi Aventis Sa | Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique |
| PE20071092A1 (es) | 2005-12-08 | 2007-12-10 | Aventis Pharma Inc | Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico |
| WO2007136571A1 (en) * | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Pro-drugs of tertiary alcohols |
| GB2438682A (en) | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| DE602006017669D1 (de) | 2006-06-12 | 2010-12-02 | Camp Scandinavia Ab | Rahmen für eine Hyperextensionsorthese |
| US8481085B2 (en) * | 2006-06-15 | 2013-07-09 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabigerol |
| GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| TW200848063A (en) * | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| US8889076B2 (en) * | 2008-12-29 | 2014-11-18 | Uop Llc | Fluid catalytic cracking system and process |
-
2008
- 2008-01-04 GB GB0800390A patent/GB2456183A/en not_active Withdrawn
- 2008-12-17 GB GB1012953.4A patent/GB2468828B/en active Active
- 2008-12-17 PL PL13152600T patent/PL2609928T3/pl unknown
- 2008-12-17 PT PT161675624T patent/PT3095452T/pt unknown
- 2008-12-17 PT PT131526006T patent/PT2609928T/pt unknown
- 2008-12-17 CN CN200880125822.5A patent/CN101939017B/zh active Active
- 2008-12-17 US US12/811,393 patent/US9017737B2/en active Active
- 2008-12-17 ES ES16167562T patent/ES2750728T3/es active Active
- 2008-12-17 WO PCT/GB2008/004217 patent/WO2009087351A1/en not_active Ceased
- 2008-12-17 EP EP08869534.1A patent/EP2249848B1/en active Active
- 2008-12-17 EP EP16167562.4A patent/EP3095452B1/en active Active
- 2008-12-17 PL PL16167562T patent/PL3095452T3/pl unknown
- 2008-12-17 ES ES13152600T patent/ES2751117T3/es active Active
- 2008-12-17 CA CA2708921A patent/CA2708921C/en active Active
- 2008-12-17 UA UAA201009705A patent/UA103472C2/uk unknown
- 2008-12-17 JP JP2010541094A patent/JP5409650B2/ja active Active
- 2008-12-17 MX MX2010007073A patent/MX2010007073A/es active IP Right Grant
- 2008-12-17 ES ES08869534.1T patent/ES2574155T3/es active Active
- 2008-12-17 BR BRPI0821461A patent/BRPI0821461A8/pt not_active IP Right Cessation
- 2008-12-17 HU HUE13152600A patent/HUE047214T2/hu unknown
- 2008-12-17 KR KR1020107017111A patent/KR101631518B1/ko active Active
- 2008-12-17 HU HUE16167562A patent/HUE046780T2/hu unknown
- 2008-12-17 AU AU2008346285A patent/AU2008346285B2/en active Active
- 2008-12-17 NZ NZ586648A patent/NZ586648A/xx unknown
- 2008-12-17 EP EP13152600.6A patent/EP2609928B1/en active Active
- 2008-12-17 RU RU2010132649/15A patent/RU2503448C2/ru active
- 2008-12-24 CL CL2008003902A patent/CL2008003902A1/es unknown
- 2008-12-29 AR ARP080105764A patent/AR070063A1/es unknown
- 2008-12-31 TW TW097151656A patent/TWI519299B/zh not_active IP Right Cessation
- 2008-12-31 TW TW103121762A patent/TW201436791A/zh unknown
-
2009
- 2009-01-05 PE PE2014000565A patent/PE20141249A1/es not_active Application Discontinuation
- 2009-01-05 PE PE2009000002A patent/PE20091361A1/es not_active Application Discontinuation
-
2010
- 2010-07-04 IL IL206784A patent/IL206784A0/en active IP Right Grant
- 2010-07-29 ZA ZA2010/05443A patent/ZA201005443B/en unknown
- 2010-08-04 CO CO10095174A patent/CO6290695A2/es not_active Application Discontinuation
-
2012
- 2012-09-21 GB GBGB1216932.2A patent/GB201216932D0/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE046780T2 (hu) | Kannabidiol használata aripiprazollal kombinálva | |
| NL350111I2 (nl) | fenpicoxamid en prothioconazool | |
| NL301340I2 (nl) | tisotumab vedotin | |
| NO2022039I1 (no) | Enfortumab vedotin | |
| NL300891I2 (nl) | Lotilaner en zouten daarvan | |
| HRP20180718T1 (hr) | Oligopeptidni spojevi i njihova upotreba | |
| HRP20160737T1 (hr) | Anti-her3-protutijela i njihove uporabe | |
| PL2452709T3 (pl) | Kaniula | |
| PL2544682T3 (pl) | Fitokannabinoidy w leczeniu glejaka | |
| BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
| EP2296593A4 (en) | MEDICAL HEAD COVER | |
| DK2245130T3 (da) | Ts23 -alpha-amylasevarianter med ændrede egenskaber | |
| HRP20160579T1 (hr) | Spoj indola i njegova farmaceutska upotreba | |
| BR112012010226A2 (pt) | artigo absorvente descartável com núcleo absorvente com perfil traçado | |
| BRPI1009863A2 (pt) | cânula com câmera e iluminação integrada | |
| BRPI0906366A2 (pt) | Inalador | |
| FI20085515A0 (fi) | Menetelmä ja järjestely turvavalaisimen yhteydessä | |
| BRPI0906367A2 (pt) | inalador | |
| HRP20182083T1 (hr) | Nova kombinacija i uporaba | |
| BRDI7106698S (pt) | Configuração aplicada em instrumento médico | |
| BRPI0906369A2 (pt) | Inalador | |
| BRDI7102651S (pt) | Configuração aplicada em instrumento médico | |
| BRDI7103033S (pt) | Configuração aplicada em instrumento médico | |
| BRDI7102976S (pt) | Configuração aplicada em instrumento médico | |
| HRP20160578T1 (hr) | Supstituirani furankarboksamidi i njihova upotreba |